EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer

Caroline J. Atkinson, Futoshi Kawamata, Cheng Liu, Sunyoung Ham, B. Györffy, Alan L. Munn, Ming Q. Wei, Andreas Möller, Vicki Whitehall, Adrian P. Wiegmans

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Epidermal growth factor receptor (EGFR) supports colorectal cancer progression via oncogenic signaling. Anti-EGFR therapy is being investigated as a clinical option for colorectal cancer, and an observed interaction between EGFR and Prion protein has been detected in neuronal cells. We hypothesized that PrP C expression levels may regulate EGFR signaling and that detailed understanding of this signaling pathway may enable identification of resistance mechanisms and new actionable targets in colorectal cancer. We performed molecular pathway analysis following knockdown of PrP C or inhibition of EGFR signaling via gefitinib to identify changes in expression of key signaling proteins that determine cellular sensitivity or resistance to cisplatin. Expression of these proteins was examined in matched primary and metastatic patient samples and was correlated for resistance to therapy and progression of disease. Utilizing three colorectal cancer cell lines, we observed a correlation between high expression of PrP C and resistance to cisplatin. Investigation of molecular signaling in a resistant cell line revealed that PrP C contributed to signaling via colocalization with EGFR, which could be overcome by targeting p38 mitogen-activated protein kinases (p38 MAPK). We revealed that the level of Krüppel-like factor 5 (KLF5), a target downstream of p38 MAPK, was predictive for cell line and patient response to platinum agents. Further, high KLF5 expression was observed in BRAF-mutant colorectal cancer. Our study indicates that the EGFR to KLF5 pathway is predictive of patient progression on platinum-based therapy.

Original languageEnglish
Pages (from-to)725-737
Number of pages13
JournalMolecular Oncology
Volume13
Issue number4
DOIs
Publication statusPublished - Apr 1 2019

Fingerprint

Platinum
Epidermal Growth Factor Receptor
Colorectal Neoplasms
p38 Mitogen-Activated Protein Kinases
Cell Line
Cisplatin
Prion Proteins
Disease Progression
Proteins
Therapeutics

Keywords

  • cisplatin
  • colorectal cancer
  • FOXO3a
  • Prion protein
  • signal transduction

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Oncology
  • Cancer Research

Cite this

EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer. / Atkinson, Caroline J.; Kawamata, Futoshi; Liu, Cheng; Ham, Sunyoung; Györffy, B.; Munn, Alan L.; Wei, Ming Q.; Möller, Andreas; Whitehall, Vicki; Wiegmans, Adrian P.

In: Molecular Oncology, Vol. 13, No. 4, 01.04.2019, p. 725-737.

Research output: Contribution to journalArticle

Atkinson, CJ, Kawamata, F, Liu, C, Ham, S, Györffy, B, Munn, AL, Wei, MQ, Möller, A, Whitehall, V & Wiegmans, AP 2019, 'EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer', Molecular Oncology, vol. 13, no. 4, pp. 725-737. https://doi.org/10.1002/1878-0261.12411
Atkinson, Caroline J. ; Kawamata, Futoshi ; Liu, Cheng ; Ham, Sunyoung ; Györffy, B. ; Munn, Alan L. ; Wei, Ming Q. ; Möller, Andreas ; Whitehall, Vicki ; Wiegmans, Adrian P. / EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer. In: Molecular Oncology. 2019 ; Vol. 13, No. 4. pp. 725-737.
@article{ee19fa7df81b4b5b8d956716943af13c,
title = "EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer",
abstract = "Epidermal growth factor receptor (EGFR) supports colorectal cancer progression via oncogenic signaling. Anti-EGFR therapy is being investigated as a clinical option for colorectal cancer, and an observed interaction between EGFR and Prion protein has been detected in neuronal cells. We hypothesized that PrP C expression levels may regulate EGFR signaling and that detailed understanding of this signaling pathway may enable identification of resistance mechanisms and new actionable targets in colorectal cancer. We performed molecular pathway analysis following knockdown of PrP C or inhibition of EGFR signaling via gefitinib to identify changes in expression of key signaling proteins that determine cellular sensitivity or resistance to cisplatin. Expression of these proteins was examined in matched primary and metastatic patient samples and was correlated for resistance to therapy and progression of disease. Utilizing three colorectal cancer cell lines, we observed a correlation between high expression of PrP C and resistance to cisplatin. Investigation of molecular signaling in a resistant cell line revealed that PrP C contributed to signaling via colocalization with EGFR, which could be overcome by targeting p38 mitogen-activated protein kinases (p38 MAPK). We revealed that the level of Kr{\"u}ppel-like factor 5 (KLF5), a target downstream of p38 MAPK, was predictive for cell line and patient response to platinum agents. Further, high KLF5 expression was observed in BRAF-mutant colorectal cancer. Our study indicates that the EGFR to KLF5 pathway is predictive of patient progression on platinum-based therapy.",
keywords = "cisplatin, colorectal cancer, FOXO3a, Prion protein, signal transduction",
author = "Atkinson, {Caroline J.} and Futoshi Kawamata and Cheng Liu and Sunyoung Ham and B. Gy{\"o}rffy and Munn, {Alan L.} and Wei, {Ming Q.} and Andreas M{\"o}ller and Vicki Whitehall and Wiegmans, {Adrian P.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1002/1878-0261.12411",
language = "English",
volume = "13",
pages = "725--737",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer

AU - Atkinson, Caroline J.

AU - Kawamata, Futoshi

AU - Liu, Cheng

AU - Ham, Sunyoung

AU - Györffy, B.

AU - Munn, Alan L.

AU - Wei, Ming Q.

AU - Möller, Andreas

AU - Whitehall, Vicki

AU - Wiegmans, Adrian P.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Epidermal growth factor receptor (EGFR) supports colorectal cancer progression via oncogenic signaling. Anti-EGFR therapy is being investigated as a clinical option for colorectal cancer, and an observed interaction between EGFR and Prion protein has been detected in neuronal cells. We hypothesized that PrP C expression levels may regulate EGFR signaling and that detailed understanding of this signaling pathway may enable identification of resistance mechanisms and new actionable targets in colorectal cancer. We performed molecular pathway analysis following knockdown of PrP C or inhibition of EGFR signaling via gefitinib to identify changes in expression of key signaling proteins that determine cellular sensitivity or resistance to cisplatin. Expression of these proteins was examined in matched primary and metastatic patient samples and was correlated for resistance to therapy and progression of disease. Utilizing three colorectal cancer cell lines, we observed a correlation between high expression of PrP C and resistance to cisplatin. Investigation of molecular signaling in a resistant cell line revealed that PrP C contributed to signaling via colocalization with EGFR, which could be overcome by targeting p38 mitogen-activated protein kinases (p38 MAPK). We revealed that the level of Krüppel-like factor 5 (KLF5), a target downstream of p38 MAPK, was predictive for cell line and patient response to platinum agents. Further, high KLF5 expression was observed in BRAF-mutant colorectal cancer. Our study indicates that the EGFR to KLF5 pathway is predictive of patient progression on platinum-based therapy.

AB - Epidermal growth factor receptor (EGFR) supports colorectal cancer progression via oncogenic signaling. Anti-EGFR therapy is being investigated as a clinical option for colorectal cancer, and an observed interaction between EGFR and Prion protein has been detected in neuronal cells. We hypothesized that PrP C expression levels may regulate EGFR signaling and that detailed understanding of this signaling pathway may enable identification of resistance mechanisms and new actionable targets in colorectal cancer. We performed molecular pathway analysis following knockdown of PrP C or inhibition of EGFR signaling via gefitinib to identify changes in expression of key signaling proteins that determine cellular sensitivity or resistance to cisplatin. Expression of these proteins was examined in matched primary and metastatic patient samples and was correlated for resistance to therapy and progression of disease. Utilizing three colorectal cancer cell lines, we observed a correlation between high expression of PrP C and resistance to cisplatin. Investigation of molecular signaling in a resistant cell line revealed that PrP C contributed to signaling via colocalization with EGFR, which could be overcome by targeting p38 mitogen-activated protein kinases (p38 MAPK). We revealed that the level of Krüppel-like factor 5 (KLF5), a target downstream of p38 MAPK, was predictive for cell line and patient response to platinum agents. Further, high KLF5 expression was observed in BRAF-mutant colorectal cancer. Our study indicates that the EGFR to KLF5 pathway is predictive of patient progression on platinum-based therapy.

KW - cisplatin

KW - colorectal cancer

KW - FOXO3a

KW - Prion protein

KW - signal transduction

UR - http://www.scopus.com/inward/record.url?scp=85063268139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063268139&partnerID=8YFLogxK

U2 - 10.1002/1878-0261.12411

DO - 10.1002/1878-0261.12411

M3 - Article

C2 - 30478887

AN - SCOPUS:85063268139

VL - 13

SP - 725

EP - 737

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 4

ER -